Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...
A recent study has analyzed the relationship between different air pollutants and the main subtypes of lung cancer.
Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...
MedPage Today on MSN
Time of Day Matters for Immunochemotherapy in Lung Cancer
This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...
SurvivorNet on MSN
Could timing give your cancer treatment a boost? New study on the best time to receive immunotherapy & chemo for non-small cell lung cancer
A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with NSCLC live longer.
Brachytherapy, a form of internal radiotherapy, has emerged as a promising treatment modality for patients with non-small cell lung cancer (NSCLC). This technique involves the precise implantation of ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results